- Partnership with China’s No. 1 medical device group aims at a patient pool of 10 million
- Regulatory "Fast-Track" expected following presidential state visit and existing bio-printing patents
- Company projects a "Quantum Jump" in revenue for the second half of 2026

ROKIT Healthcare (KOSDAQ: 376900), an AI-driven hyper-personalized organ regeneration platform specialist led by CEO Seokhwan You, announced today that it has signed a strategic partnership agreement with WEGO Group, the leading medical device provider in China, to commercialize its AI-driven organ regeneration platform.

The agreement comes as President Lee Jae-myung’s state visit to China has revitalized economic cooperation between the two nations. ROKIT Healthcare is positioned as a notable beneficiary of this diplomatic momentum, moving to capture a significant share of the KRW 1.4 trillion Chinese skin regeneration market through this alliance with China's top medical device group.

Beyond a technical collaboration, this partnership establishes a streamlined infrastructure for China-wide production, distribution, and licensing managed by WEGO Group. This effectively secures what the company describes as an "AI-driven organ regeneration highway" for its expansion into the Chinese market. The deal is being recognized as a major milestone, leveraging favorable bilateral policies, ROKIT’s existing patent portfolio in China, and a partnership with a dominant market player.

In the current climate of Korea-China cooperation in the AI, bio, and healthcare sector, ROKIT Healthcare is highly likely to qualify for the "Fast-Track" licensing process with China’s National Medical Products Administration (NMPA). Based on these developments, the company anticipates immediate commercialization and revenue generation starting in the second half of this year.

The partner, WEGO Group, is China’s premier healthcare conglomerate headquartered in Shandong Province. Known as the "Johnson & Johnson of China," WEGO maintains an extensive logistics network and dominates hospital supply chains across the country.

WEGO Group reportedly sought this partnership to coincide with the state visit, citing the innovative nature of ROKIT Healthcare’s platform. They highlighted the company's multi-pipeline capabilities in skin, cartilage, and kidney regeneration, as well as its proprietary "additive-free cryo-forming" technology, as key factors that provide a distinct competitive advantage.

The potential scale of the Chinese market is significant. A representative from WEGO Group stated, "The target population in China for conditions such as diabetic foot ulcers (DFU), burns, and skin cancer is nearly 10 million. Securing just 10% of this market would represent a value of approximately $1 billion (KRW 1.4 trillion). This has the potential to be one of the most significant achievements for a single medical device partnership in the history of KOSDAQ-listed bio companies."

A representative from ROKIT Healthcare added, "This collaboration with WEGO Group demonstrates how diplomatic milestones can be converted into tangible corporate growth. With our core patents and the backing of China’s No. 1 distribution network, we project explosive growth in the Chinese market beginning in the second half of 2026."